Comprehensive and Accurate Molecular Profiling of Breast Cancer Through MRNA Expression of , , , , and a Novel Proliferation Signature

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Feb 10

PMID 38337757

Authors

Anne-Sophie Wegscheider

Joanna Gorniak

Sara Rollinson

Leanne Gough

Navdeep Dhaliwal

Agustin Guardiola

Anna Gasior

Denise Helmer

Zoe Pounce

Axel Niendorf

Affiliations

Soon will be listed here.

Abstract

Background: An accurate status determination of breast cancer biomarkers (ER, PR, HER2, Ki67) is crucial for guiding patient management. The "gold standard" for assessing these biomarkers in FFPE tissue is IHC, which faces challenges in standardization and exhibits substantial variability. In this study, we compare the concordance of a new commercial RT-qPCR kit with IHC in determining BC biomarker status.

Methods: The performance was evaluated using 634 FFPE specimens, which underwent histological analysis in accordance with standard of care methods. HER2 2+ tumors were referred to ISH testing. An immunoreactive score of ≥2/12 was considered positive for ER/PR and 20% staining was used as a cut-off for Ki67 high/low score. RT-qPCR and results calling were performed according to the manufacturer's instructions.

Results: High concordance with IHC was seen for all markers (93.2% for ER, 87.1% for PR, 93.9% for HER2, 77.9% for Ki67 and 80.1% for proliferative signature (assessed against Ki67 IHC)).

Conclusions: By assessing the concordance with the results obtained through IHC, we sought to demonstrate the reliability and utility of the kit for precise BC subtyping. Our findings suggest that the kit provides a highly precise and accurate quantitative assessment of BC biomarkers.

Citing Articles

Breast Cancer Molecular Subtype Prediction: A Mammography-Based AI Approach.

Mota A, Mendes J, Matela N Biomedicines. 2024; 12(6).

PMID: 38927578 PMC: 11201998. DOI: 10.3390/biomedicines12061371.

References

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y . Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29(8):2110-2120. PMC: 10427426. DOI: 10.1038/s41591-023-02478-2. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Jurikova M, Danihel L, Polak S, Varga I . Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016; 118(5):544-52. DOI: 10.1016/j.acthis.2016.05.002. View

Dowsett M, Nielsen T, AHern R, Bartlett J, Coombes R, Cuzick J . Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22):1656-64. PMC: 3216967. DOI: 10.1093/jnci/djr393. View

Caselli E, Pelliccia C, Teti V, Bellezza G, Mandarano M, Ferri I . Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS One. 2021; 16(9):e0255580. PMC: 8460001. DOI: 10.1371/journal.pone.0255580. View

Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-1712. PMC: 6246241. DOI: 10.1093/annonc/mdx308. View

Li T, Zeng H, Shan Z, Ye R, Cheang T, Zhang Y . Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell Int. 2020; 20:123. PMC: 7161125. DOI: 10.1186/s12935-020-01191-1. View

Bevers T, Helvie M, Bonaccio E, Calhoun K, Daly M, Farrar W . Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(11):1362-1389. DOI: 10.6004/jnccn.2018.0083. View

10.

Focke C, Burger H, van Diest P, Finsterbusch K, Glaser D, Korsching E . Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. 2017; 84:219-227. DOI: 10.1016/j.ejca.2017.07.041. View

11.

Lu Y, Yang G, Xiao Y, Zhang T, Su F, Chang R . Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis. Breast Cancer. 2020; 27(5):903-911. DOI: 10.1007/s12282-020-01086-z. View

12.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

13.

Nielsen T, Leung S, Rimm D, Dodson A, Acs B, Badve S . Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2020; 113(7):808-819. PMC: 8487652. DOI: 10.1093/jnci/djaa201. View

14.

Song X, Zhang T, Wang X, Liao X, Han C, Yang C . Distinct Diagnostic and Prognostic Values of Kinesin Family Member Genes Expression in Patients with Breast Cancer. Med Sci Monit. 2018; 24:9442-9464. PMC: 6322372. DOI: 10.12659/MSM.913401. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7):e48-72. DOI: 10.5858/134.7.e48. View

17.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013; 138(2):241-56. PMC: 4086638. DOI: 10.5858/arpa.2013-0953-SA. View

18.

Markl B, Fuzesi L, Huss R, Bauer S, Schaller T . Number of pathologists in Germany: comparison with European countries, USA, and Canada. Virchows Arch. 2020; 478(2):335-341. PMC: 7969551. DOI: 10.1007/s00428-020-02894-6. View

19.

Harris L, Ismaila N, McShane L, Andre F, Collyar D, Gonzalez-Angulo A . Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(10):1134-50. PMC: 4933134. DOI: 10.1200/JCO.2015.65.2289. View

20.

Liu F, Wu Y, Mi Y, Gu L, Sang M, Geng C . Identification of core genes and potential molecular mechanisms in breast cancer using bioinformatics analysis. Pathol Res Pract. 2019; 215(7):152436. DOI: 10.1016/j.prp.2019.152436. View